株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

過剰性腸症候群:パイプライン製品の分析

Irritable Bowel Syndrome - Pipeline Review, H1 2018

発行 Global Markets Direct 商品コード 232842
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.05円で換算しております。
Back to Top
過剰性腸症候群:パイプライン製品の分析 Irritable Bowel Syndrome - Pipeline Review, H1 2018
出版日: 2018年05月08日 ページ情報: 英文 120 Pages
概要

過剰性腸症候群(IBS)は、慢性的あるいは再発性の免疫反応を伴う症状や、消化管の炎症を表す用語です。症候は、腹部のけいれんや痛み、血の混じった下痢、体重の減少、食欲の不振、および熱などです。素因として、年齢、家族歴、喫煙、鎮痛剤などがあげられます。治療には、副腎皮質ステロイド、免疫抑制剤、抗生物質、鎮静薬などを用います。

当レポートでは、世界各国での過剰性腸症候群(IBS)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

過剰性腸症候群の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

過剰性腸症候群の治療薬開発に従事している企業

  • 4D Pharma PLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann SpA
  • Allergan Plc
  • Ardelyx Inc
  • アステラス製薬
  • CJ HealthCare Corp
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co., Ltd.
  • エーザイ
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals Inc
  • キッセイ薬品
  • Lexicon Pharmaceuticals Inc
  • Napo Pharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • 大日本住友製薬
  • Synergy Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc

薬剤プロファイル

過剰性腸症候群:休止中のプロジェクト

過剰性腸症候群:開発が中止された製品

過剰性腸症候群:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

目次
Product Code: GMDHC10403IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 6, 1, 8 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Irritable Bowel Syndrome - Overview
  • Irritable Bowel Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Irritable Bowel Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
  • 4D Pharma PLC
  • Allergan Plc
  • Ardelyx Inc
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co Ltd
  • Eisai Co Ltd
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • ImmuneBiotech AB
  • Ironwood Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Metacrine Inc
  • Napo Pharmaceuticals Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc
  • Irritable Bowel Syndrome - Drug Profiles
  • BC-1261 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bedoradrine sulfate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Blautix - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Canchew Plus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CIN-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • crofelemer DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSTI-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DA-6886 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DSP-6952 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • E-2508 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EB-410 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EB-420 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-3179106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IB-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • linaclotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • linaclotide DR2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lovastatin MR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LT-4006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ondansetron hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OP-687 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PR-38 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RDX-023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • relenopride hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rifamycin CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00310941 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solabegron - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tenapanor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VB-210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Irritable Bowel Syndrome - Dormant Projects
  • Irritable Bowel Syndrome - Discontinued Products
  • Irritable Bowel Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Apr 25, 2018: FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
  • Apr 03, 2018: AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew Product Throughout South Korea
  • Mar 26, 2018: RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA for IBS-D
  • Jan 17, 2018: Outpost Medicine Announces Acceptance of Two Investigational New Drug Applications for OP-687 by U.S. FDA
  • Jan 16, 2018: Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US
  • Jan 16, 2018: RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA for IBS-D
  • Jan 04, 2018: OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer
  • Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C
  • Dec 12, 2017: Cosmo Pharmaceuticals Announces First Patient Randomized In Its Proof Of Concept Phase II Clinical Trial Of Rifamycin SV In IBS-D
  • Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo's FDA-approved Human Prescription Drug
  • Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
  • Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
  • Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
  • Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D
  • Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2018
  • Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2018
  • Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2018
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Irritable Bowel Syndrome - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Irritable Bowel Syndrome - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top